Incannex receives ethics approval to commence phase 1 clinical trial of multi-use anti-inflammatory drug ihl-675a

Highlights: bellberry human research ethics committee approved the phase 1 clinical trial investigating safety and pharmacokinetics of ihl-675a on july 20, 2022 the trial will be performed at cmax clinical research, a dedicated and experienced clinical trial centre in australia, and managed by avance clinical the trial will assess the pharmacokinetics, safety, and tolerability of combination cannabinoid drug ihl-675a trial data will be applicable to regulatory submissions for all three ihl-675a development programs, rheumatoid arthritis, inflammatory bowel disease and lung inflammation formulation and manufacturing of ihl-675a soft gel capsules for the clinical trial has been completed; long term stability studies are ongoing patient recruitment is scheduled to commence in august 2022 melbourne, australia , july 21, 2022 /prnewswire/ -- incannex healthcare limited (nasdaq: ixhl) (asx: ihl), ('incannex' or the 'company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has received approval from the bellberry human research ethics committee ('hrec') for a phase 1 clinical trial investigating its proprietary multi-use, anti-inflammatory drug ihl-675a. ihl-675a is a combination cannabinoid drug comprising cannabidiol ('cbd') and hydroxychloroquine ('hcq') in a fixed dose combination.
IXHL Ratings Summary
IXHL Quant Ranking